Sun Pharmaceutical Industries Ltd. announced on Friday it gained permission from Drugs Controller General of India to begin a clinical trial for COVID-19 treatment with Nafamostat Mesilate.
Nafamostat, an anticoagulant employed to treat acute pancreatitis, has been approved for human use in Japan and South Korea for over a decade.
Clinical trials of the drug have already started in Germany and the Netherlands.
What's happening in Tunisia?
Subscribe to our Youtube channel for updates.
